[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613836":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":54,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":25,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Aarhus University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group 1","EXPERIMENTAL","Denosumab",[13],"Drug: Denosumab",{"label":15,"type":16,"description":17,"interventionNames":18},"Study group 2","PLACEBO_COMPARATOR","Placebo",[19],"Drug: Saline (0.9% NaCl)",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Denosumab 60 mg",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":29},"Saline (0.9% NaCl)",[15],[17],[31],{"name":32,"affiliation":5,"role":33},"Bente Langdahl, MD, Professor, DMSc, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Anne Sophie Sølling, MD, PhD","CONTACT","+45 22 30 05 24","annesoel@rm.dk",[41],{"facility":5,"status":42,"city":43,"state":25,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Aarhus","Denmark","DK",{"type":47,"coordinates":48},"Point",[49,50],10.21076,56.15674,{"lat":50,"lon":49},[53],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"type":33,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Anne Sophie Sølling","MD, PhD, postdoc",[58],{"name":59,"class":60},"Sponsor: MD, Professor, DMSc, PhD Bente Lomholt Langdahl","UNKNOWN","100613836","phase-4-the-effect-of-denosumab-on-muscle-and-strength-and-insulin-sensitivity-100613836",false,"NCT07271771","The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity","DENMUSIN","Inclusion Criteria:\n\n* Postmenopausal women (postmenopausal for at least two years)\n* Age ≥ 40 years\n* BMD T-score ≥ -2.0 (lumbar spine, total hip or femoral neck)\n* At least 2 lumbar vertebrae that can be evaluated by dual-energy x-ray absorptiometry (DXA)\n* Diabetes Mellitus type 2\n* Treatment with metformin as monotherapy\n\nExclusion Criteria:\n\n* Treatment for osteoporosis at any time\n* Other antidiabetic medication than metformin\n* Low-energy vertebral fractures at any time\n* Low-energy hip fracture at any time\n* Ongoing treatment with systemic glucocorticoids\n* Metabolic bone disease (for example osteogenesis imperfecta, Paget's disease of bone, hyperparathyroidism)\n* Treatment affecting bone, calcium metabolism or muscle\n* Active cancer within the last 5 years with the exception of basal cell skin cancer\n* Estimated glomerular filtration rate (eGFR) ≤ 35 mL\u002Fmin\n* Unable to read and understand Danish\n* Immobility","FEMALE","40 Years",{"count":71,"type":72},40,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","Randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.",[78],"Osteoporosis",[80,81,82,83],"muscle","insulin sensitivity","denosumab","bone mineral density","2025-12-08",{"date":86,"type":87},"2025-12-15","ACTUAL",{"date":89,"type":87},"2024-05-21",{"date":91,"type":72},"2027-03-01",{"name":5,"class":6},1]